The estimated Net Worth of William R Larue is at least $7.41 mil dollars as of 21 December 2022. Mr. Larue owns over 120 units of TRACON Pharmaceuticals Inc stock worth over $536 and over the last 9 years he sold TCON stock worth over $6,876. In addition, he makes $0 as Independent Director at TRACON Pharmaceuticals Inc.
William has made over 3 trades of the TRACON Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 120 units of TCON stock worth $151 on 21 December 2022.
The largest trade he's ever made was buying 6,545 units of TRACON Pharmaceuticals Inc stock on 26 July 2021 worth over $25,002. On average, William trades about 436 units every 97 days since 2015. As of 21 December 2022 he still owns at least 7,763 units of TRACON Pharmaceuticals Inc stock.
You can see the complete history of Mr. Larue stock trades at the bottom of the page.
William R. LaRue serves as Independent Director of the Company. He served as the Chief Financial Officer, Senior Vice President and Treasurer at Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from June 2006 until its acquisition by Mallinckrodt plc in March 2014, and from April 2007 to March 2014, he served as the Assistant Secretary at Cadence. Prior to joining Cadence Pharmaceuticals, Inc., Mr. LaRue was the Senior Vice President and Chief Financial Officer of Micromet, Inc. (formerly CancerVax Corporation), a biotechnology company, from 2001 to 2006. From 2000 to 2001, Mr. LaRue served as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Previously, he was the Vice President and Treasurer of Safeskin Corporation, a medical device company, from 1997 to 2000 and the Treasurer of GDE Systems, Inc., a high technology electronic systems company from 1993 to 1997. Mr. LaRue currently serves on the board of directors of Conatus Pharmaceuticals, Inc., a position he has held since February 2017. In addition, since December 2017 Mr. LaRue has served on the board of directors of Oncternal Therapeutics, Inc., a cancer therapeutics company that entered into a reverse merger agreement with GTx, Inc. in March 2019, and also serves on the board of directors of Alastin Skincare, Inc., a private innovative skincare company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.
William LaRue is 69, he's been the Independent Director of TRACON Pharmaceuticals Inc since 2014. There are no older and 14 younger executives at TRACON Pharmaceuticals Inc.
William's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include: